Company Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 01:36:35 2024-06-11 pm EDT			5-day change	1st Jan Change
3.21 ^USD	+0.94%		+1.92%	+4.64%

May. 16	Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes	CI
May. 16	Aileron Therapeutics, Inc. Announces Executive Changes	CI

Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Number of employees: 15

Managers	Title	Age	Since
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
David Annis CTO	Chief Tech/Sci/R&D Officer	51	07-10-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
Liz Melone IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Josef H. Von Rickenbach CHM	Chairman	68	19-06-18
Alan Musso BRD	Director/Board Member	62	23-10-30
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
Reinhard Ambros BRD	Director/Board Member	67	13-05-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
William Fairey BRD	Director/Board Member	60	23-10-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,589,576	20,619,682 ( 95.51 %)	0	95.51 %
Stock B	0	24,610	0	0

Name	Equities	%	Valuation
University of Texas Investment Management Co. 8.292 %	1,790,142	8.292 %	6 M $
BIOS Capital Management LP 7.232 %	1,561,375	7.232 %	5 M $
Alerce Investment Management LP 3.847 %	830,466	3.847 %	3 M $
Nantahala Capital Management LLC 1.181 %	255,000	1.181 %	816 000 $
Senvest Management LLC 1.069 %	230,895	1.069 %	738 864 $
Circle K Invesco LP 0.4994 %	107,819	0.4994 %	345 021 $
Geode Capital Management LLC 0.3231 %	69,759	0.3231 %	223 229 $
Sigma Planning Corp. 0.3149 %	67,985	0.3149 %	217 552 $
Renaissance Technologies LLC 0.2087 %	45,064	0.2087 %	144 205 $
Vanguard Group, Inc. (Subfiler) 0.1867 %	40,314	0.1867 %	129 005 $

Aileron Therapeutics, Inc.

12407 North Mopac Expressway Suite 250

78758, Austin

http://www.aileronrx.com

address Aileron Therapeutics, Inc.(ALRN)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.18 USD

Average target price

13 USD

Spread / Average Target

+308.81%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AILERON THERAPEUTICS, INC.	+6.28%	68.65M
VERTEX PHARMACEUTICALS INCORPORATED	+18.41%	125B
REGENERON PHARMACEUTICALS, INC.	+14.05%	108B
BIONTECH SE	-6.97%	23.64B
ARGENX SE	+2.39%	22.39B
GENMAB A/S	-12.11%	17.78B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-14.41%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+0.49%	13.56B
SAREPTA THERAPEUTICS, INC.	+25.12%	11.59B

Bio Therapeutic Drugs